Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2019 | Intensive chemotherapy for AML: do we still need it?

Christoph Röllig • 15 Jun 2019
EHA 2019
Acute Myeloid Leukemia

Christoph Röllig, MD, Dresden University of Technology, Dresden, Germany, discusses the treatment options for acute myeloid leukemia (AML), and whether intensive chemotherapy is still clinically relevant. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Christoph Röllig

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed CBF-AML 2:41
Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed CBF-AML
Christoph Röllig • 5 Dec 2025
Challenges associated with relapsed AML and the value of targeted agents 2:52
Challenges associated with relapsed AML and the value of targeted agents
Christoph Röllig • 3 Sep 2025
Insights into the VINCENT trial: venetoclax + azacitidine versus intensive chemotherapy in NPM1m AML 2:18
Insights into the VINCENT trial: venetoclax + azacitidine versus intensive chemotherapy in NPM1m AML
Christoph Röllig • 3 Sep 2025
Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML 2:19
Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML
Christoph Röllig • 11 Dec 2023

Related Videos

Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia 1:48
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia
Michael Savona • 6 Dec 2025
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML 1:31
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen • 6 Dec 2025
The development and international validation of an unsupervised classification model in AML 1:28
The development and international validation of an unsupervised classification model in AML
Amin Turki • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals